12% Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel Get link Facebook X Pinterest Email Other Apps GlobeNewswire Get link Facebook X Pinterest Email Other Apps